Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact

Boston Scientific reported sales growth of 1.5% and adjusted EPS of $0.73, below the cited expectations of 3%–5% growth and $0.80–$0.82 EPS. Management attributed the shortfall primarily to an eight-day cyberattack disruption, estimated to have cost 300 basis points of sales growth and $0.07 in adjusted EPS; it guided for 3.75% sales growth in 2026 and said 2027 is expected to be the cycle trough. Shares fell 5.81% to $42.44 on volume 234% above the three-month average, while the article noted potential upside from the pending Penumbra acquisition if integration succeeds.

Analysis

The key question is whether the cyber-related shortfall is deferred activity or lost demand. If procedures and orders were postponed, revenue can recover as systems normalize; if hospital ordering, product availability, or clinician confidence remains impaired, the reported cost estimate will understate the earnings drag. A slow recovery also creates operating-leverage risk: delayed growth can weigh on earnings beyond the disruption itself, while management’s multi-year product pipeline is not yet evidence of a near-term offset.

The acquisition adds a second execution burden. Integration work could compete for management attention and operating resources precisely while BSX is rebuilding its core business. Penumbra has deal-related upside optionality, but without terms and closing milestones in the supplied data, that is not enough to underwrite a standalone long. Relative performance versus Medtronic and Abbott suggests the weakness is company-specific today, though one session does not establish a durable divergence.

Near term, elevated trading volume raises the chance of a sharp countertrend bounce, making an immediate momentum short less attractive. Over 1–3 months, look for an operational update and evidence that orders and procedures are normalizing. Over 6–18 months, product launches and integration execution matter more than the initial cyber estimate. The contrarian opportunity is that a temporary interruption may be priced as a prolonged reset; confirmation is missing. Thesis is falsified by further guidance cuts, persistent operating disruption, or evidence of sustained demand loss.

Key Decisions for Investors

• Avoid buying BSX solely on the lower share price. Keep it on a watchlist and require evidence of restored order flow and stable procedure volumes before adding exposure.
• For a relative-value expression, consider a small, risk-limited short BSX / long Medtronic position only if BSX continues to underperform after its systems are operating normally. Close or reassess if BSX reports a clear recovery or the peer spread reverses; a relief rally is a material near-term risk.
• Track BSX’s next guidance update for sales growth, adjusted EPS, and any quantified cyber-related costs. Further cuts or persistent disruption would strengthen the bearish case; recovery toward prior operating expectations would weaken it.
• Treat Penumbra as a deal-monitoring situation, not a confirmed beneficiary: verify transaction terms, closing conditions, and integration milestones before making a position decision.